Breaking News

Financial Report: Pfizer

By Kristin Brooks | January 28, 2014

Enbrel collaboration expiry, continued erosion of Lipitor hurt results

Pfizer
 
4Q Revenues: $13.6 billion (-2%)

4Q Earnings: $2.6 billion (-59%)

FY Revenues: $51.6 billion (-6%)

FY Earnings: $22.0 billion (+51%)

Comments: Primary Care and Specialty Care revenues were $3.4 billion in the quarter, down 10% and 7%, respectively. Emerging Markets revenue was $2.7 billion, up 4%. Established Products revenue was $2.4 billion, up 2%. Consumer Healthcare sales were $943 million, up 1%. Oncology sales were up 26% to $468 million. Revenues in the quarter reflect an operational growth of 1%, and the unfavorable impact of foreign exchange of 3%. Sales were up for Lyrica (+11%), Inlyta (+117%) and Xalkori (+98%), Enbrel outside of North America (+5%), as well as Celebrex (+6%), primarily in the U.S. Revenues were impacted by the expiration of the collaboration agreement for Enbrel in North America, and continued erosion of Lipitor, the ongoing expiration of the Spiriva collaboration in certain countries, as well as other product losses of exclusivity in certain markets. In June Pfizer completed the disposition of its Animal Health business (Zoetis). Revenues in the quarter included $65 million from the transitional manufacturing and supply agreements with Zoetis.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks